Short-Term High-Fat Diet (HFD) Induced Anxiety-Like Behaviors and Cognitive Impairment Are Improved with Treatment by Glyburide
Stephen J. Gainey1,2 
Kristin A. Kwakwa2 
Julie K. Bray2 
Melissa M. Pillote2 
Vincent L. Tir2 Albert E. Towers2,3 
Gregory G. Freund1,2,3*- 1Department of Animal Sciences, University of Illinois, Urbana, IL, USA
- 2Department of Pathology, Program in Integrative Immunology and Behavior, University of Illinois College of Medicine, Urbana, IL, USA
- 3Department of Nutritional Sciences, University of Illinois, Urbana, IL, USA
Obesity-associated comorbidities such as cognitive impairment and anxiety are increasing public health burdens that have gained prevalence in children. To better understand the impact of childhood obesity on brain function, mice were fed with a high-fat diet (HFD) from weaning for 1, 3 or 6 weeks. When compared to low-fat diet (LFD)-fed mice (LFD-mice), HFD-fed mice (HFD-mice) had impaired novel object recognition (NOR) after 1 week. After 3 weeks, HFD-mice had impaired NOR and object location recognition (OLR). Additionally, these mice displayed anxiety-like behavior by measure of both the open-field and elevated zero maze (EZM) testing. At 6 weeks, HFD-mice were comparable to LFD-mice in NOR, open-field and EZM performance but they remained impaired during OLR testing. Glyburide, a second-generation sulfonylurea for the treatment of type 2 diabetes, was chosen as a countermeasure based on previous data exhibiting its potential as an anxiolytic. Interestingly, a single dose of glyburide corrected deficiencies in NOR and mitigated anxiety-like behaviors in mice fed with HFD-diet for 3-weeks. Taken together these results indicate that a HFD negatively impacts a subset of hippocampal-independent behaviors relatively rapidly, but such behaviors normalize with age. In contrast, impairment of hippocampal-sensitive memory takes longer to develop but persists. Since single-dose glyburide restores brain function in 3-week-old HFD-mice, drugs that block ATP-sensitive K+ (KATP) channels may be of clinical relevance in the treatment of obesity-associated childhood cognitive issues and psychopathologies.
Introduction
With over one billion overweight and obese individuals afflicted, world-wide overnutrition is a significant threat to human health (Kelly et al., 2008). Obesity is associated with increased susceptibility to various comorbidities like depression (Leckie and Withers, 1967; Luppino et al., 2010), type 2 diabetes (Wannamethee and Shaper, 1999), cardiovascular disease (Wannamethee et al., 1998), and cancer (Vainio and Bianchini, 2002). One of the root causes of obesity is attributed to ingestion of dietary fat (Lissner and Heitmann, 1995) which parallels the global permeation of a “western diet” (Cordain et al., 2005), where nearly 33% of total energy derives from fat. Predictably, extension of the obese phenotype into childhood is associated with added risks including diminished cognition and executive function (Liang et al., 2014). Additionally, obese children are susceptible to certain psychological complications like attention deficit hyperactivity disorder (ADHD), impulsivity, inattention and anxiety (Daniels et al., 2005; Kalarchian and Marcus, 2012). Current work demonstrates that childhood and adolescent obesity is disadvantageous, especially as psychological illness and/or cognitive impairment persists even when consumption of a high-fat diet (HFD) is well in the past (Wang et al., 2015). Given the projected prevalence of childhood obesity in the next 30 years (Ogden et al., 2014) and the magnitude of associated co-morbidities, identifying therapeutics to address this accelerating health concern is crucial.
Cognitive impairment and psychological abnormalities described in mouse models of diet-induced obesity (DIO; Buettner et al., 2012) are often connected to a reduction in molecules associated with neurogenesis and/or learning/memory such as brain derived neurotrophic factor (BDNF; Molteni et al., 2002), dopamine (DA; Kaczmarczyk et al., 2013) and inflammatory bioactives (Pistell et al., 2010). Recent studies demonstrate that DIO-associated brain dysfunction is not solely attributable to these mechanisms because hippocampal-based memory impaired by dietary fat occurs without significant change in BDNF (Heyward et al., 2013). Along similar lines, prolonged HFD-feeding does not upregulate brain-based IL-1β, TNF-α or IL-6 mRNA, even though sickness-like behaviors suggestive of brain inflammation are observed (Lavin et al., 2011). In juvenile animals, however, a HFD can impact working through pathways tied to glucocorticoids, neurogenesis and leptin (Boitard et al., 2012, 2014, 2015; Valladolid-Acebes et al., 2013), and it was found that this exposure impacted cognition in adulthood (Boitard et al., 2012). Although the brain-based complications of obesity are phenotypically well-described in animals, pharmacologic interventions that overcome such morbidities that are easily translated into humans are lacking.
The second-generation sulfonylurea, glyburide, has long been used in the treatment of type 2 diabetes (Kolterman et al., 1984; Groop, 1992). Glyburide inhibits sulfonylurea receptor 1 (Sur1) preventing KATP channel function (Ashcroft, 2005). It is this action on pancreatic β-cells that results in insulin release and improved blood glucose homeostasis (Niki et al., 1989; Zini et al., 1991). In turn, glyburide shows promise as is a promising brain therapeutic due to its ability to cross the blood-brain barrier (Simard et al., 2012). Since it has been explored as a countermeasure for traumatic brain injury (TBI), stroke, and spinal cord injury, it may be a suitable agent for other injuries and diseases as well (Kunte et al., 2007; Simard et al., 2009a,b; Patel et al., 2010). While glyburide has been explored as a mitigating agent in Alzheimer’s disease (Lavretsky and Jarvik, 1992), neuroinflammation (Lamkanfi et al., 2009; Koh et al., 2011) and oxidative stress-associated brain injury (Nazaroglu et al., 2009), little is known about the impact of sulfonylureas on the mental function of the disease it was originally designed to treat. To determine whether the sulfonylurea, glyburide, positively impacts HFD-induced cognitive impairment and anxiety-like behaviors in young mice, such behaviors were examined in animals 1, 3 and 6 weeks post-weaning fed with a low-fat or HFD. Thus, this pre-clinical study examines the role of glyburide as a deployable countermeasure to combat brain dysfunction associated with the early-life ingestion of a HFD.
Materials and Methods
Animals
The use of animals was in accordance with the Institutional Animal Care and Use Committee (IACUC) approved protocols at the University of Illinois Urbana, IL, USA. C57BL/6J male mice (3–4 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were placed on experimental diet 1 week after (between 4–5 weeks of age prior to puberty) arrival to allow for acclimation. Mice were group-housed (8 per cage), unless otherwise noted, in shoebox cages (length 46.9 cm; width 25.4 cm; height 12.5 cm) and allowed free access to food and water. Housing temperature (72°F) and humidity (45–55%) were controlled as was a 12/12 h reversed dark-light cycle (light = 1000–2200 h). All behavioral and biochemical experiments were performed in the dark cycle and separate cohorts to eliminate repeated measures as a factor. Individual mice were used in a single behavioral test. Total number of mice used was 396.
Diets, Weights, Blood Glucose
Mice were initially fed a standard chow of NIH-31 modified open formula (Teklad 7013, Madison, WI, USA) containing 18% calories from protein, 6.2% from fat and 45% from carbohydrates. Mice were then transferred to a feed of open source uniform-base diets, for respective studies, containing either 10% calories from fat (low-fat diet [LFD]; D12450B, Research Diets, New Brunswick, NJ, USA) or 60% calories from fat (HFD; D12492, Research Diets, New Brunswick, NJ, USA). Both diets provided 20% calories from protein. Mouse weight was recorded for the respective weeks using an Adventurer Pro digital scale (Ohaus, Parsippany, NJ, USA). Blood glucose testing results were recorded for the respective weeks by fasting mice for 12 h during their light cycle and sampling tail blood. For glyburide studies, blood glucose testing was conducted immediately post-behavior testing with ad libitum access to food. Glucose was quantified by using an AlphaTRAK blood glucose monitoring system (Abbott Laboratories, North Chicago, IL, USA).
Food Intake
As previously described (York et al., 2012), mouse cohorts used to determine food intake were individually housed for up to 6 weeks. Food intake was calculated daily as the difference in weight of food in the feed bowl before and after removal from the food intake arena.
Plasma Non-Esterified Fatty Acids (NEFAs)
As described previously (Moon et al., 2014), mice were euthanized and blood collected via cardiac puncture using BD Microtainer Tubes with Lithium Heparin (BD Diagnostics, Franklin Lakes, NJ, USA). Blood was centrifuged at 8000× g for 10 min at 4°C. Supernatant was collected and analyzed. The resultant plasma non-esterified fatty acids (NEFA) were measured on an AU 680 Chemistry System (Beckman Coulter, Brea, CA, USA) using an enzymatic colorimetric NEFA test kit (Wako, Richmond, VA, USA). This kit is designed to measure total NEFA levels excluding short-chain fatty acids.
Injectables
Glyburide (6.6 mg/kg/mouse; Sigma-Aldrich, St. Louis, MO, USA) was administered IP as described (Chiu et al., 2014) immediately prior to novel object training for mice at 1, 3 and 6 weeks on diet. Mice were injected 4 h prior to elevated zero maze (EZM) measured in mice on diet for 3 weeks only.
Novel Object Recognition (NOR)
Testing was performed as described in the studies by Chiu et al. (2012) and York et al. (2012). In brief, group housed mice were transferred to a shoebox-style training arena (26 cm × 48 cm × 21 cm) containing two identical objects (LEGO toys in distinct configurations) on one side of the arena. Mice were allowed to investigate the objects for 24 h with food provided ad libitum. After training, mice were returned to their home cage for 1 h. After the 1 h refractory period, subject mice were transferred to individual testing arenas, without food but with bedding, where they were presented with one familiar object and one novel object in a spatial location comparable to training. Mouse exploration was video recorded for 5 min and evaluated by using EthoVision XT 7 video tracking software (Noldus Information Technology, Leesburg, VA, USA). A discrimination index was used to determine cognition and calculated as the amount of time spent examining the novel object divided by the total time spent investigating both objects.
Object Location Recognition (OLR)
Testing was performed as described (York et al., 2012) and was similar to novel object recognition (NOR) except that upon testing the subject mouse was re-exposed to two familiar objects (LEGO toys) where one was placed at the opposite end from training. Spatial clues were placed on the outside of the cage to assist spatial determination. As above, mouse exploration was video recorded for 5 min and evaluated by using EthoVision XT 7 video tracking software. A discrimination index was used to determine cognition and calculated as the amount of time spent examining the object in a novel location divided by the total time spent investigating both objects.
Elevated Zero-Maze
Testing was performed as described in the study by York et al. (2012). In brief, group-housed mice were individually housed for 24 h. For testing, subject mice were individually placed within the high walls of an EZM (57.15 cm outer diameter, 6 cm track, 72 cm from the floor). The maze was composed of four quadrants with two areas having high walls (14 cm tall) and two areas without walls. Mouse exploration was video recorded for 5 min and evaluated by using EthoVision XT 7 video tracking software. Time spent in the open quadrants was defined as at least 50% of the body being outside of the high-walled areas.
Open Field Test
As above, group-housed mice were individual housed for 24 h. Mice were individually tested by placing subject mice in a lit novel open field arena (66 cm × 45.7 cm × 22.9 cm) generating a 9 cm shadow from respective side walls (York et al., 2012). Mouse exploration was video recorded for 5 min and evaluated by using EthoVision XT 7 video tracking software. Time spent in the open area was equated to time spent in the non-shadowed areas.
Glutathione Assay
As previously described, PBS perfused brain regions were frozen in liquid nitrogen then freeze fractured (Kaczmarczyk et al., 2013) in reaction buffer containing 50 mM NaCl (Fisher Scientific, Fair Lawn, NJ, USA), 1 mM EDTA, 50 mM HEPES, pH 7.0 (USB Corporation, Cleveland, OH, USA) using the TissueLyser II (Qiagen, Valencia, CA, USA) at a rotational frequency of 30 s−1 for 2 min. Lysates were centrifuged at 10,000× g for 15 min at 4°C and the supernatant recovered. The supernatant was deproteinated with an equal volume of metaphosphoric acid (Sigma-Aldrich, St. Louis, MO, USA) and vortexing. Samples were re-centrifuged at 8000× g for 5 min. Supernatant and pellets were saved. Glutathione, both reduced and oxidized, was determined using the Glutathione Assay Kit (Cayman Chemical, Ann Arbor, Michigan) following the manufacturer’s instructions. Glutathione (GSH) and glutathione disulfide (GSSG) were quantified using an ELx800 Absorbance Microplate Reader (BioTek Instrument, Winooski, VT, USA) at 405 nm in 5 min intervals for 30 min. Protein precipitates were eluted with reaction buffer and quantified using the DC Protein Assay (Bio-Rad, Hercules, CA, USA).
Quantitative PCR (qPCR)
Brain regions were dissected from PBS perfused whole brains and RNA isolated (York et al., 2012). RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (PN 4368813; Applied Biosystems, Foster City, CA, USA). The TaqMan Gene Expression primers used were: IL1R2 (Mm00439622_m1), BDNF (MM01334042_m1), Arc (Mm01204954_g1), iNOS (Mm00440502_m1), eNOS (Mm00435217_m1), casp1 (Mm00438023_m1), TXNIP (Mm01265659_g1), and superoxide dismutase (SOD1; Mm01344233_g1). Quantitative PCR (qPCR) was performed on a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA). To compare gene expression, a parallel amplification of endogenous RPS3 (Mm00656272_m1) was performed. Reactions with no reverse transcription and no template were included as negative controls. Relative quantitative evaluation of target gene to RPS3 was performed by comparing the values of ΔCts, where Ct is the threshold concentration.
Statistical Analysis
Data analysis was conducted using Sigma Plot11.2 (Systat Software, Chicago, IL, USA). Body weight, fasting blood glucose (FBG), plasma NEFA, food intake, NOR and object location recognition (OLR) total investigation, EZM performance, open field testing (OFT), and PCR analysis used one-way analysis of variance (ANOVA) to define the main effects followed by Tukey adjustment. All experiments with NOR and OLR discrimination index analyzed using a one-sample t-test comparing novel object preference to chance level of 0.5. The Kruskal-Wallis one-way ANOVA on ranks was used for GSH:GSSG ratio for analyzing the main effect of diet and treatment in glyburide experiment, due to variance within groups. Glyburide experiments for blood glucose were analyzed by two-way ANOVA and time spent in open of EZM and closed arm entries by one-way ANOVA test to determine the main effects of diet and treatment followed by a Tukey adjustment. Statistical significance was assumed at p < 0.05 and all data are presented as means ± SEM.
Results
HFD Feeding for 3 Weeks Increases Body Weight and Blood Glucose Without Impacting Plasma NEFA Concentrations, Food Ingestion, and Inflammatory Gene Expression
To delineate the physiologic impact of the diets administered, the aforementioned biometrics were examined after 1, 3 and 6 weeks of feeding. When HFD-mice were compared to LFD-mice at 3 and 6 weeks post feeding, there was a 30% and 42% increase, respectively, in FBG levels. These findings correlated with a 13.4% and 28.4% rise in body weight, respectively (see Table 1). Interestingly, food intake was comparable in HFD-mice and LFD-mice, but this resulted in a 37%, 28%, and 14% increase in calories ingested in HFD-mice after 1, 3 and 6 weeks of feeding, respectively (see Table 1). Since HFD-associated brain-based inflammation is implicated in cognitive impairment, biomarkers of pro-inflammation were examined (Table 2). Interestingly, only hippocampal iNOS gene transcripts in HFD-mice showed an upregulation (99% vs. LFD-mice).
Table 1. Body weight (g), blood glucose (mg/dL), plasma NEFA (mEq/L), food intake (g/d), and energy intake (kcal/g/d) of mice fed with LFD or HFD.
Table 2. Impact of LFD or HFD feeding on gene expression in the hippocampus and amygdala after 3 weeks of feeding.
HFD-Mice Develop Object Memory Impairment and Transient Anxiety-Like Behaviors
HFD-mice and LFD-mice were examined after 1, 3 and 6 weeks of diet using a NOR task (Figure 1A). NOR is an effective measure of hippocampal-independent memory (Wan et al., 1999; Brown and Aggleton, 2001; McGaugh, 2004). At 1 and 3 weeks of diet, HFD-mice showed no preference for a novel object while LFD-mice showed preference for novel objects over that of the familiar ones (one-sample t-test: 1 week diet (LFD)- P < 0.001, 3 week diet (LFD)- P < 0.022; Figure 1A). After 6 weeks of diet, however, HFD-mice developed novel object preference which was similar to that of LFD-mice (one-sample t-test: 6 week diet (LFD)- P < 0.001, 6 week diet (HFD)- P = 0.005; Figure 1A). As an additional control, LFD-mice and chow-fed mice were compared. After 1 week of feeding, NOR performance in chow-fed and LFD-mice were comparable (one-sample t-test: SC- P = 0.002, LFD- P = 0.001; Figure 1B). HFD-mice and LFD-mice demonstrated similar total object exploration times (one-way ANOVA: 1 week diet- F(1,22) = 0.08; P = 0.785, 3 week diet- F(1,22) = 1.22; P = 0.281, 6 week diet- F(1,22) = 0.317; P = 0.579; Figure 1D).
Figure 1. High-fat diet (HFD) mice develop object memory impairment and transient anxiety-like behaviors. HFD-mice (HFD), low-fat diet (LFD)-mice, and/or standard chow-mice (SC) underwent novel object recognition (NOR) at the times indicated (NOR) (A), and at 1 week after diet (B). HFD-mice (HFD) and LFD-mice (LFD) underwent object location recognition (OLR) testing at the times indicated (C). Total time spent investigating both novel and familiar objects were determined for NOR (D) and OLR (E). HFD-mice and LFD-mice were examined using elevated zero maze (EZM) (F) and the open field test (OFT) (G). Discrimination index for NOR and OLR was defined as time spent exploring novelty divided by time spent investigating both objects. All results are expressed as means ± SEM; n = 4–16, values with an asterisk are significant at p < 0.05, using one-sample t-test with novel object preference compared with chance level of 0.5 and one-way analysis of variance (ANOVA).
When hippocampal-memory was examined using OLR (Kesner et al., 1993; Broadbent et al., 2004; Jablonski et al., 2013) a persistent memory impairment was identified in HFD-mice compared to that of LFD-mice (Figure 1B). After 1 week of diet OLR was not impacted in HFD-mice (one-sample t-test: 1 week diet (LFD)- P < 0.001, 1 week diet (HFD)- P = 0.018; Figure 1C). However, after a period of 3 and 6 weeks of diet, HFD-mice lacked preference for the novel object whereas LFD-mice were able to distinguish between novel and familiar in the OLR task (one-sample t-test: 3 week diet (LFD)- P = 0.048, 6 week diet (LFD)- P < 0.001; Figure 1C). As above, diet did not impact combined object exploration (one-way ANOVA: 1 week diet- F(1,12) = 1.870; P = 0.197, 3 week diet- F(1,14) = 1.281; P = 0.277, 6 week diet- F(1,22) = 0.565; P = 0.460; Figure 1E).
To explore the impact of a HFD on anxiety-like behavior mice were tested in an EZM. After 3 weeks of diet, time spent in the center of the EZM was reduced in HFD-mice compared to the time spent by LFD-mice (one-way ANOVA: F(1,30) = 10.333; P = 0.003; Figure 1F). After 1 or 6 weeks of diet, no difference between LFD-mice and HFD-mice was observed. To further explore if a HFD engendered trait as opposed to state anxiety (Moon et al., 2015), the OFT was utilized (Prut and Belzung, 2003). HFD-mice spent a decreased amount of time in the open area of the OFT after 3 weeks of diet when compared to LFD-mice (one-way ANOVA: F(1,23) = 4.446; P = 0.047; Figure 1G) and a similar amount of time in open after 1 or 6 weeks of diet.
The GSH:GSSG Ratio in the Amygdala and Hippocampus is Reduced by an HFD
Since antioxidant capacity can impact memory (Alzoubi et al., 2013; Xu et al., 2014) brain GSH and GSSG was examined. After 3 weeks of diet, there was a 54% and 43% increase in the GSH:GSSG ratios in the amygdala and hippocampus, respectively, when LFD-mice were compared to HFD-mice (Kruskal-Wallis one-way ANOVA: amygdala- Q = 2.935; P = 0.038; Figure 2A, hippocampus- Q = 2.449; P = 0.014; Figure 2B). GSH:GSSG ratios were not different in LFD-mice and HFD-mice after 1 and 6 weeks of diet. Glyburide, which is known to increase antioxidant capacity (Patel et al., 1987; Chugh et al., 2001), raised the GSH:GSSG ratio 32.3% in the amygdala, in HFD-mice after 3 weeks of diet (Kruskal-Wallis one-way ANOVA: Amygdala- Q = 2.748; P = 0.050; Figure 2C).
Figure 2. The GSH:GSSG ratio in the amygdala and hippocampus is reduced by a HFD. Glutathione (GSH) and glutathione disulfide (GSSG) were measured in HFD and LFD-mice and presented as GSH:GSSG in both the amygdala (A) and hippocampus (B). GSH:GSSG ratios in amygdala and hippocampus of HFD-mice injected with glyburide (C). Results are expressed as means ± SEM, n = 5–10, values with an asterisk are significant, p < 0.05 using Kruskal-Wallis one-way ANOVA on ranks.
Glyburide Reduces Anxiety-Like Behaviors Associated with a HFD After 3 Weeks of Diet
After glyburide treatment, HFD-mice and LFD-mice spent equivalent times exploring the open and closed arms of the EZM (one-way ANOVA: Gly- F(1,35) = 0.277; P = 0.602; Figure 3A; F(1,35) = 0.166; P = 0.686; Figure 3B). Importantly, injection of saline did not prevent anxiety-like behaviors associated with a HFD (one-way ANOVA: Sal- F(1,33) = 4.460; P = 0.043; Figure 3A; F(1,33) = 6.264; P = 0.018; Figure 3B). HFD-mice and LFD-mice did not differ in distance moved in the EZM (see Figure 3C). As expected, post hoc analysis showed that glyburide resulted in a 16.5% reduction in non-FBG levels (two-way ANOVA: HFD (Sal vs. Gly)- Q = 4.506; P = 0.003; Figure 3D) and was associated with an overall drug effect (two-way ANOVA: Sal vs. Gly- F(1,41) = 9.418; P = 0.004; Figure 3D).
Figure 3. Glyburide reduces anxiety-like behaviors associated with a HFD after 3 weeks of diet. HFD and LFD-mice were administered either saline or glyburide and examined after 4 h in an EZM. Time in the open (A) and closed arms (B) are presented. Similarly treated HFD- and LFD-mice were examined for locomotion (C), and post-behavior blood glucose (D). All results are expressed as mean ± SEM; n = 10–18, values without a common subscript or asterisk are different (a vs. b, p < 0.05) with (A,B) analyzed using one-way ANOVA and (C,D) using two-way ANOVA.
Memory is Improved by Glyburide in HFD-Mice After 3 Weeks of Diet
At 1, 3 and 6 weeks of diet, HFD-mice were unable to discriminate novelty in the NOR and OLR tasks (one-sample t-test: 1 week NOR (LFD-Sal)- P = 0.013, 1 week (HFD-sal)- P = 0.249; Figure 4A; 3 week NOR (LFD-Sal)- P = 0.008, 3 week (HFD-Sal)- P = 0.089; Figure 4B; 3 week OLR (LFD-Sal)- P < 0.001, 3 week (HFD-Sal)- P = 0.145; Figure 4C; 6 week OLR (LFD-Sal)- P = 0.005, 6 week (HFD-Sal)- P = 0.644; Figure 4D). Interestingly, glyburide restored novelty preference in HFD-mice in the NOR task after 3 weeks of diet (one-sample t-test: 3 week NOR (LFD-Gly)- P = 0.025, (HFD-Gly)- P < 0.001; Figure 4B), but not at 1 or 6 weeks of diet (one-sample t-test: 1 week NOR (LFD-Gly)- P = 0.018, 1 week (HFD-Gly)- P = 0.165; Figure 4A; 6 week OLR (LFD-Gly)- P = 0.002, 6 week (HFD-Gly)- P = 0.915; Figure 4D) and not for OLR (one-sample t-test: 3 week OLR (LFD-Gly)- P 0.014, 3 week (HFD-Gly)- P = 0.351; Figure 4C).
Figure 4. Memory is improved by glyburide in HFD-mice after 3 weeks of diet. HFD and LFD-mice were administered either saline or glyburide after a 1 week of diet and examined using NOR testing (A). HFD- and LFD-mice were administered either saline or glyburide after a 3 weeks of diet and examined using NOR (B) and OLR (C) testing. HFD and LFD mice were administered either saline or glyburide after a 6 weeks of diet and examined using OLR (D) testing. Discrimination index was defined as time spent exploring novelty divided by time spent investigating both objects. Results are expressed as means ± SEM; n = 4–6, values with an asterisk are significant at p < 0.05, using one-sample t-test with novel object preference compared with chance level of 0.5.
Discussion
Overweight children are predisposed to social and emotional complications tied to overnutrition including depression, low self-esteem and learning problems (Mellbin and Vuille, 1989; Daniels et al., 2005). Origination of these learning problems is associated with inferior social skills (Dietz, 1998) and anxiety (Williams, 2001). In addition, controversy exists as to whether the overweight/obese phenotype is a root cause of childhood social and emotional problems or a sequela of resultant bullying (Eisenberg et al., 2003). In juvenile mice, a short-term (1-week) HFD feeding impairs behavior as we have previously shown (Kaczmarczyk et al., 2013) and as shown here (Figure 1A). Consistently, impaired NOR appears associated with short-term overnutrition, as opposed to impaired OLR which takes longer to manifest (3 weeks; Figure 1B). Interestingly, this early impairment in NOR is not associated with FBG or plasma NEFAs but does positively correlate with energy intake (Table 1). These findings support the contention that learning problems associated with overnutrition are not entirely linked to the overweight/obese body type and its negative perception by industrialized peoples (Murray et al., 2009; Holloway et al., 2011).
Another important finding is that impairment of OLR is longer lasting than impairment of NOR (Figure 1). The advantage of using NOR and OLR for memory testing is that they are easy to perform, involve a similar paradigm but test different types of memory. NOR is much more hippocampal-independent than is OLR (Wan et al., 1999; Brown and Aggleton, 2001; McGaugh, 2004). In contrast, OLR is more dependent on spatial memory and is, thus, more hippocampal-sensitive (Moses et al., 2005). Our findings are supported by recent work which shows that 23 weeks of HFD feeding in mice impairs OLR but not NOR (Heyward et al., 2013). In addition, we previously found that NOR was intact in HFD-mice on diet for 10–12 weeks (Lavin et al., 2011). Taken together, the clinical significance of these works is their relationship to dementia and type 3 diabetes (T3D; de la Monte and Wands, 2008).
In T3D, lack of brain-based insulin production or the presence of brain-based insulin resistance (Biessels et al., 1998; Lannert and Hoyer, 1998; Kodl and Seaquist, 2008) precipitates memory dysfunction with symptomatology that overlaps that of Alzheimer’s disease (Gasparini et al., 2001; Steen et al., 2005; Deng et al., 2009). Insulin is required for new memory creation by facilitating synaptic plasticity (van der Heide et al., 2006) and HFD-induced insulin/IGF-1 resistance (Spielman et al., 2014) which appears important to T3D (Watson and Craft, 2004; Vardy et al., 2007), especially in the hippocampus (McNay et al., 2010; Grillo et al., 2015). Given that HFD-mice have an elevation in FBG (Table 1), it is not surprising that impairment in hippocampal-dependent memory would be coincident (Figure 1). Furthermore, HFD-induced elevations in FBG are caused by insulin resistance (Hirosumi et al., 2002). What was not anticipated is the rapidity by which a HFD impairs hippocampal memory. Although Beilharz et al. (2014) found a similar phenomenon in their study, they concluded that dietary sugar was the critical factor. Sugar availability (~6.7% sucrose) was low in the diets used here. Thus, the hippocampal memory impairment observed appears dependent on fat content not on the sugar content.
Previous work by André et al. (2014) showed cognitive impairment and anxiety-like behaviors in mice fed with HFD. In their study, the postulated mechanism was tied to pro-inflammatory cytokines and indoleamine 2, 3-dioxygenase (IDO) activity. In contrast, Kaczmarczyk et al. (2013) demonstrated no brain-based pro-inflammation in HFD-exposed mice and that IDO knockout mice were as susceptible to HFD-induced memory impairment as were the controls. A key difference between the studies of Kaczmarczyk et al. (2013) and André et al. (2014) was the length of diet which was marked shorter in the latter’s study. Finally, Del Rio et al. (2016) fed juvenile mice a short-term HFD resulting in cognitive deficits and an anti-depressive phenotype. Anxiety-like behaviors were not observed, but the diet that Del Rio et al. (2016) used contained 45% fat as opposed to the 60% used in this study.
Why a HFD impacts hippocampal-independent functions like NOR and anxiety-like behaviors (Figures 1A,D,E) rapidly and transiently is not clear. Previous work shows that oxidative stress is deleterious to brain function (Shukitt-Hale, 1999; Dröge and Schipper, 2007). Specifically, anxiety-like behaviors manifest in mice when the GSH:GSSG ratio is reduced and cytosolic reactive oxygen species are increased (Llorente-Folch et al., 2013). While Figure 2 shows a drop in the GSH:GSSG ratio in HFD-mice compared to LFD-mice, this result appears as a consequence of a HFD-induced suppression of a rise in the GSH:GSSG ratio. Interestingly, 7 weeks marks the approximate sexual maturation of male C57BL/6J mice (range 6–8 weeks; Fox and Witham, 1997). Thus, male sexual maturation appears to be accompanied by a spike in the brain GSH:GSSG ratio (Figure 2). Mechanistically, this observation may be tied to an increase in testosterone since brain GSH in mice (Atroshi et al., 1990) is augmented by its administration. Additionally, sexual maturation increases the brain-active antioxidant dehydroepiandrosterone (DHEA; Hopper and Yen, 1975; McIntosh and Berdanier, 1991; Aly et al., 2011), and DHEA favorably impacts the hippocampus in neurodegenerative diseases (Charalampopoulos et al., 2008). Glyburide, especially during uncontrolled diabetes, increased reduced glutathione (Chugh et al., 2001). Such findings lend credence to our results demonstrating that glyburide increased the GSH:GSSG ratio in the brain. However, this effect appears brain-region specific, when the amygdala and hippocampus are compared.
As Figures 3, 4 illustrate, an acute single dose of glyburide prevents HFD-induced memory impairment and anxiety-like behaviors indicating a role for this sulfonylurea in overnutrition-associated brain dysfunction in juvenile mice. Previously, we demonstrated that glyburide can block the activation of brain caspase-1 triggered by adenosine (Chiu et al., 2014) which is a key biologic in hypoxia-induced anterograde amnesia (Chiu et al., 2012). Since overnutrition is associated with endoplasmic reticulum (ER) stress (Mollica et al., 2011), it is theorized that the overnutrition-associated oxidative stress causes dysregulated purine metabolism (Al-Rubaye and Morad, 2013). Subsequent cellular release of ATP and its precursors rapidly increases the interstitial concentration of adenosine (Chiu and Freund, 2014) which through the A2A adenosine receptor triggers neuronal hyperpolarization in a KATP channel dependent manner (Popoli et al., 2002). Hence the relevance of adenosine to neurodegeneration and sleep (Portas et al., 1997; Stone, 2005) and the interest in caffeine and its derivatives as neuroprotectants and CNS stimulants (Schwarzschild et al., 2002; Barranco Quintana et al., 2007). Interestingly, a recent study identified the P2X7 receptor as a potential link between anxiety in rats and a HFD (Dutheil et al., 2016). This study, however, demonstrated HFD-induced brain inflammation as the potential mechanism. As noted, brain-based inflammation was not observed here likely due to our use of a short-term HFD feeding. Dutheil et al. (2016) fed rats an HFD for 16 weeks. Thus, different pathways are likely at play during the early (3 week) and late (12–16 week) manifestations of anxiety associated with a HFD.
Glyburide can also boost SOD and catalase activity (Nazaroglu et al., 2009) mitigating oxidative stress in a canonical fashion. However, due to its limited impact on blood glucose (Figure 3), this mechanism seems unlikely In HFD-mice fed with fat for at least 6 weeks, memory-impairment may be due to hyperglycemia and the role blood glucose has in elevating extracellular amyloid-β protein in the hippocampus (Macauley et al., 2015).
In summary, short-term HFD-feeding induces both cognitive impairment and anxiety-like behaviors which parallel symptoms seen in childhood obesity. These results coincide with a reduction in antioxidant capacity as exhibited by a suppressed GSH:GSSG ratio. Importantly, we demonstrated that administration of glyburide ameliorated hippocampal-independent brain function in HFD-mice. Unfortunately glyburide did not influence the hippocampal-sensitive memory task tested. Concordantly, glyburide increased the GSH:GSSG ratio in the amygdala but not in the hippocampus. Therefore, glyburide appears to selectively increase antioxidant capacity in the brain resulting in mitigation of hippocampal-independent impairments linked to a short term exposure to a HFD. These results suggest a unique use for glyburide in the prevention of anxiety and hippocampal-independent cognitive impairment. While the exact mechanism of action requires further study, antioxidant capacity appears to be an important glyburide target.
Author Contributions
KAK, JKB, MMP, and VLT contirbuted to the acquisition, analysis, and interpretation of the behavioral and biochemical data. SJG contributed to the design, acquisition, analysis, and interpretation of the whole of this manuscript. AET contributed to the design, interpretation, and revision of all aspects of this manuscript. GGF contributed to the design, analysis and interpretation of all aspects of this manuscript. All authors worked on drafting and reviewing this manuscript, and approved the final version for publication.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This research was supported by the National Institutes of Health (DK064862 to GGF).
Abbreviations
DA, dopamine; DHEA, dehydroepiandrosterone; DIO, diet induced obesity; DOPAC, 3, 4-dihydroxyphenylacetic acid; EZM, elevated zero maze; FBG, fasting blood glucose; GSH, glutathione; GSSG, glutathione disulfide; HFD, high fat diet; HFD-mice, high-fat diet mice; HVA, homovanillic acid; IDO, indoleamine 2, 3 deoxygenase; LFD, low fat diet; LFD-mice, low-fat diet mice; NEFA, non-esterified fatty-acids; NOR, novel object recognition; OFT, open field test; OLR, object location recognition; SOD, superoxide dismutase.
References
Al-Rubaye, F. G., and Morad, T. S. (2013). Purine metabolism and oxidative stress in children with autistic spectrum disorders. J. Exp. Integr. Med. 3, 293–297. doi: 10.5455/jeim.130813.or.085
Aly, H. F., Metwally, F. M., and Ahmed, H. H. (2011). Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s disease. Acta Biochim. Pol. 58, 513–520.
Alzoubi, K. H., Khabour, O. F., Salah, H. A., and Hasan, Z. (2013). Vitamin E prevents high-fat high-carbohydrates diet-induced memory impairment: the role of oxidative stress. Physiol. Behav. 119, 72–78. doi: 10.1016/j.physbeh.2013.06.011
André, C., Dinel, A. L., Ferreira, G., Layé, S., and Castanon, N. (2014). Diet-induced obesity progressively alters cognition, anxiety-like behavior and lipopolysaccharide-induced depressive-like behavior: focus on brain indoleamine 2,3 dioxygenase activation. Brain Behav. Immun. 41, 10–21. doi: 10.1016/j.bbi.2014.03.012
Ashcroft, F. M. (2005). ATP-sensitive potassium channelopathies: focus on insulin secretion. J. Clin. Invest. 115, 2047–2058. doi: 10.1172/jci25495
Atroshi, F., Paulin, L., Paalanen, T., and Westermarck, T. (1990). Glutathione level in mice brain after testosterone administration. Adv. Exp. Med. Biol. 264, 199–202. doi: 10.1007/978-1-4684-5730-8_32
Barranco Quintana, J. L., Allam, M. F., Serrano Del Castillo, A., and Fernández-Crehuet Navajas, R. (2007). Alzheimer’s disease and coffee: a quantitative review. Neurol. Res. 29, 91–95. doi: 10.1179/174313206X152546
Beilharz, J. E., Maniam, J., and Morris, M. J. (2014). Short exposure to a diet rich in both fat and sugar or sugar alone impairs place, but not object recognition memory in rats. Brain Behav. Immun. 37, 134–141. doi: 10.1016/j.bbi.2013.11.016
Biessels, G. J., Kamal, A., Urban, I. J., Spruijt, B. M., Erkelens, D. W., and Gispen, W. H. (1998). Water maze learning and hippocampal synaptic plasticity in Streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 800, 125–135. doi: 10.1016/s0006-8993(98)00510-1
Boitard, C., Cavaroc, A., Sauvant, J., Aubert, A., Castanon, N., Laye, S., et al. (2014). Impairment of hippocampal-dependent memory induced by juvenile high-fat diet intake is associated with enhanced hippocampal inflammation in rats. Brain Behav. Immun. 40, 9–17. doi: 10.1016/j.bbi.2014.03.005
Boitard, C., Etchamendy, N., Sauvant, J., Aubert, A., Tronel, S., Marighetto, A., et al. (2012). Juvenile, but not adult exposure to high-fat diet impairs relational memory and hippocampal neurogenesis in mice. Hippocampus 22, 2095–2100. doi: 10.1002/hipo.22032
Boitard, C., Maroun, M., Tantot, F., Cavaroc, A., Sauvant, J., Marchand, A., et al. (2015). Juvenile obesity enhances emotional memory and amygdala plasticity through glucocorticoids. J. Neurosci. 35, 4092–4103. doi: 10.1523/JNEUROSCI.3122-14.2015
Broadbent, N. J., Squire, L. R., and Clark, R. E. (2004). Spatial memory, recognition memory and the hippocampus. Proc. Natl. Acad. Sci. U S A 101, 14515–14520. doi: 10.1073/pnas.0406344101
Brown, M. W., and Aggleton, J. P. (2001). Recognition memory: what are the roles of the perirhinal cortex and hippocampus? Nat. Rev. Neurosci. 2, 51–61. doi: 10.1038/35049064
Buettner, R., Schölmerich, J., and Bollheimer, L. C. (2012). High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 15, 798–808. doi: 10.1038/oby.2007.608
Charalampopoulos, I., Remboutsika, E., Margioris, A. N., and Gravanis, A. (2008). Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol. Metab. 19, 300–307. doi: 10.1016/j.tem.2008.07.004
Chiu, G. S., Chatterjee, D., Darmody, P. T., Walsh, J. P., Meling, D. D., Johnson, R. W., et al. (2012). Hypoxia/Reoxygenation impairs memory formation via adenosine-dependent activation of caspase-1. J. Neurosci. 32, 13945–13955. doi: 10.1523/JNEUROSCI.0704-12.2012
Chiu, G. S., Darmody, P. T., Walsh, J. P., Moon, M. L., Kwakwa, K. A., Bray, J. K., et al. (2014). Adenosine through the A2A adenosine receptor increases IL-1β in the brain contributing to anxiety. Brain Behav. Immun. 41, 218–231. doi: 10.1016/j.bbi.2014.05.018
Chiu, G. S., and Freund, G. G. (2014). Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illness. Metabolism 63, 1491–1498. doi: 10.1016/j.metabol.2014.09.003
Chugh, S. N., Dhawan, R., Kishore, K., Sharma, A., and Chugh, K. (2001). Glibenclamide vs. gliclzide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus—a double blind randomized study. J. Assoc. Physicians India 49, 803–807.
Cordain, L., Boyd Eaton, S., Sebastian, A., Mann, N., Lindeberg, S., Watkins, B. A., et al. (2005). Origins and evolution of the Western diet: health implications for the 21st century. Am. J. Clin. Nutr. 81, 341–354.
Daniels, S. R., Arnett, D. K., Eckel, R. H., Gidding, S. S., Hayman, L. L., Kumanyika, S., et al. (2005). Overweight in children and adolescents: pathophysiology, consequences, prevention and treatment. Circulation 111, 1999–2012. doi: 10.1161/01.cir.0000161369.71722.10
de la Monte, S. M., and Wands, J. R. (2008). Alzheimer’s disease is type 3 diabetes-evidence reviewed. J. Diabetes Sci. Technol. 2, 1101–1113. doi: 10.1177/193229680800200619
Del Rio, D., Morales, L., Ruiz-Gayo, M., and Del Olmo, N. (2016). Effect of high-fat diets on mood and learning performance in adolescent mice. Behav. Brain Res. 311, 167–172. doi: 10.1016/j.bbr.2016.04.052
Deng, Y., Li, B., Liu, Y., Igbal, K., Grundke-Igbal, I., and Gong, C. X. (2009). Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer’s disease. Am. J. Pathol. 175, 2089–2098. doi: 10.2353/ajpath.2009.090157
Dietz, W. H. (1998). Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 101, 518–525.
Dröge, W., and Schipper, H. M. (2007). Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 6, 361–370. doi: 10.1111/j.1474-9726.2007.00294.x
Dutheil, S., Ota, K. T., Wohleb, E. S., Rasmussen, K., and Duman, R. S. (2016). High-fat diet induced anxiety and anhedonia: impact on brain homeostasis and inflammation. Neuropsychopharmacology 41, 1874–1887. doi: 10.1038/npp.2015.357
Eisenberg, M. E., Neumark-Sztainer, D., and Story, M. (2003). Associations of weight-based teasing and emotional well-being among adolescents. Arch. Pediatr. Adolesc. Med. 157, 733–738. doi: 10.1001/archpedi.157.8.733
Fox, R. R., and Witham, B. (1997). The Jackson Laboratory Handbook on Genetically Standardized JAX Mice. 5th Edn. Maine: The Jackson Laboratory.
Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., et al. (2001). Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21, 2561–2570.
Grillo, C. A., Piroli, G. G., Lawrence, R. C., Wrighten, S. A., Green, A. J., Wilson, S. P., et al. (2015). Hippocampal insulin resistance impairs spatial learning and synaptic plasticity. Diabetes 64, 3927–3936. doi: 10.2337/db15-0596
Groop, L. C. (1992). Sulfonylureas in NIDDM. Diabetes Care 15, 737–754. doi: 10.2337/diacare.15.6.737
Heyward, F. D., Walton, R. G., Carle, M. S., Coleman, M. A., Garvey, W. T., and Sweatt, J. D. (2013). Adult mice maintained on a high-fat diet exhibit object location memory deficits and reduced hippocampal SIRT1 gene expression. Neurobiol. Learn. Mem. 98, 25–32. doi: 10.1016/j.nlm.2012.04.005
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., et al. (2002). A central role for JNK in obesity and insulin resistance. Nature 420, 333–336. doi: 10.1038/nature01137
Holloway, C. J., Cochlin, L. E., Emmanuel, Y., Murray, A., Codreanu, I., Edwards, L. M., et al. (2011). A high-fat diet impairs cardiac high-energy phosphate metabolism and cognitive function in healthy human subjects. Am. J. Clin. Nutr. 93, 748–755. doi: 10.3945/ajcn.110.002758
Hopper, B. R., and Yen, S. S. (1975). Circulating concentrations of dehydroepiandrosterone and dehydroepiandrosterone sulfate during puberty. J. Clin. Endocrinol. Metab. 40, 458–461. doi: 10.1210/jcem-40-3-458
Jablonski, S. A., Schreiber, W. B., Westbrook, S. R., Brennan, L. E., and Stanton, M. E. (2013). Determinants of novel object and location recognition during development. Behav. Brain Res. 256, 140–150. doi: 10.1016/j.bbr.2013.07.055
Kaczmarczyk, M. M., Machaj, A. S., Chiu, G. S., Lawson, M. A., Gainey, S. J., York, J. M., et al. (2013). Methylphenidate prevents high-fat diet (HFD)-induced learning/memory impairment in juvenile mice. Psychoneuroendocrinology 38, 1553–1564. doi: 10.1016/j.psyneuen.2013.01.004
Kalarchian, M. A., and Marcus, M. D. (2012). Psychiatric comorbidity of childhood obesity. Int. Rev. Psychiatry 24, 241–246. doi: 10.3109/09540261.2012.678818
Kelly, T., Yang, W., Chen, C. S., Reynolds, K., and He, J. (2008). Global burden of obesity in 2005 and predictions to 2030. Int. J. Obes. (Lond) 32, 1431–1437. doi: 10.1038/ijo.2008.102
Kesner, R. P., Bolland, B. L., and Dakis, M. (1993). Memory for spatial locations, motor responses and objects: triple dissociation among the hippocampus, caudate nucleus and extrastriate visual cortex. Exp. Brain Res. 93, 462–470. doi: 10.1007/BF00229361
Kodl, C. T., and Seaquist, E. R. (2008). Cognitive dysfunction and diabetes mellitus. Endocr. Rev. 29, 494–511. doi: 10.1210/er.2007-0034
Koh, G. C., Maude, R. R., Schreiber, M. F., Limmathurotsakul, D., Wiersinga, W. J., Wuthiekanun, V., et al. (2011). Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin. Infect. Dis. 52, 717–725. doi: 10.1093/cid/ciq202
Kolterman, O. G., Gray, R. S., Shapiro, G., Scarlett, J. A., Griffin, J., and Olefsky, J. M. (1984). The acute and chronic effects of sulfonylurea therapy in Type II diabetic subjects. Diabetes 33, 346–354. doi: 10.2337/diab.33.4.346
Kunte, H., Schmidt, S., Eliasziw, M., del Zoppo, G. J., Simard, J. M., Masuhr, F., et al. (2007). Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 38, 2526–2530. doi: 10.1161/strokeaha.107.482216
Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., et al. (2009). Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187, 61–70. doi: 10.1083/jcb.200903124
Lannert, H., and Hoyer, S. (1998). Intracerebroventricular administration of Streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 112, 1199–1208. doi: 10.1037/0735-7044.112.5.1199
Lavin, D. N., Joesting, J. J., Chiu, G. S., Moon, M. L., Meng, J., Dilger, R. N., et al. (2011). Fasting induces an anti-inflammatory effect on the neuroimmune system which a high-fat diet prevents. Obesity (Silver Spring) 19, 1586–1594. doi: 10.1038/oby.2011.73
Lavretsky, E. P., and Jarvik, L. F. (1992). A group of potassium-channel blockers-acetylcholine releasers: new potentials for Alzhemer disease? A review. J. Clin. Psychopharmacol. 12, 110–118. doi: 10.1097/00004714-199204000-00006
Leckie, E. V., and Withers, R. F. (1967). Obesity and depression. J. Psychosom. Res. 11, 107–115. doi: 10.1016/0022-3999(67)90063-3
Liang, J., Matheson, B. E., Kaye, W. H., and Boutelle, K. N. (2014). Neurocognitive correlates of obesity and obesity-related behaviors in children and adolescents. Int. J. Obes. (Lond) 38, 494–506. doi: 10.1038/ijo.2013.142
Lissner, L., and Heitmann, B. L. (1995). Dietary fat and obesity: evidence from epidemiology. Eur. J. Clin. Nutr. 49, 79–90.
Llorente-Folch, I., Sahún, I., Contreras, L., Casarejos, M. J., Grau, J. M., Saheki, T., et al. (2013). AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway. J. Neurochem. 124, 347–362. doi: 10.1111/jnc.12096
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W., et al. (2010). Overweight, obesity and depression: a systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 67, 220–229. doi: 10.1001/archgenpsychiatry.2010.2
Macauley, S. L., Stanley, M., Caesar, E. E., Yamada, S. A., Raichle, M. E., Perez, R., et al. (2015). Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo. J. Clin. Invest. 125, 2463–2467. doi: 10.1172/JCI79742
McGaugh, J. L. (2004). The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu. Rev. Neurosci. 27, 1–28. doi: 10.1146/annurev.neuro.27.070203.144157
McIntosh, M. K., and Berdanier, C. D. (1991). Antiobesity effects of dehydroepiandrosterone are mediated by futile substrate cycling in hepatocytes of BHE/cdb rats. J. Nutr. 121, 2037–2043.
McNay, E. C., Ong, C. T., McCrimmon, R. J., Cresswell, J., Bogan, J. S., and Sherwin, R. S. (2010). Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol. Learn. Mem. 93, 546–553. doi: 10.1016/j.nlm.2010.02.002
Mellbin, T., and Vuille, J.-C. (1989). Further evidence of an association between psychosocial problems and increase in relative weight between 7 and 10 years of age. Acta Paediatr. Scand. 78, 576–580. doi: 10.1111/j.1651-2227.1989.tb17939.x
Mollica, M. P., Lionetti, L., Putti, R., Cavaliere, G., Gaita, M., and Barletta, A. (2011). From chronic overfeeding to hepatic injury: role of endoplasmic reticulum stress and inflammation. Nutr. Metab. Cardiovasc. Dis. 21, 222–230. doi: 10.1016/j.numecd.2010.10.012
Molteni, R., Barnard, R. J., Ying, Z., Roberts, C. K., and Gómez-Pinilla, F. (2002). A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity and learning. Neuroscience 112, 803–814. doi: 10.1016/S0306-4522(02)00123-9
Moon, M. L., Joesting, J. J., Blevins, N. A., Lawson, M. A., Gainey, S. J., Towers, A. E., et al. (2015). IL-4 knock out mice display anxiety-like behavior. Behav. Genet. 45, 451–460. doi: 10.1007/s10519-015-9714-x
Moon, M. L., Joesting, J. J., Lawson, M. A., Chiu, G. S., Blevins, N. A., Kwakwa, K. A., et al. (2014). The saturated fatty acid, palmitic acid, induces anxiety-like behavior in mice. Metabolism 63, 1131–1140. doi: 10.1016/j.metabol.2014.06.002
Moses, S. N., Cole, C., Driscoll, I., and Ryan, J. D. (2005). Differential contributions of hippocampus, amygdala and perirhinal cortex to recognition of novel objects, contextual stimuli and stimulus relationships. Brain Res. Bull. 67, 62–76. doi: 10.1016/j.brainresbull.2005.05.026
Murray, A. J., Knight, N. S., Cochlin, L. E., McAleese, S., Deacon, R. M., Rawlins, J. N., et al. (2009). Deterioration of physical performance and cognitive function in rats with short-term high-fat feeding. FASEB J. 23, 4353–4360. doi: 10.1096/fj.09-139691
Nazaroglu, N. K., Sepici-Dincel, A., and Altan, N. (2009). The effects of sulfonylurea glyburide on superoxide dismutase, catalase and glutathione peroxidase activities in the brain tissue of streptozotocin-induced diabetic rat. J. Diabetes Complications 23, 209–213. doi: 10.1016/j.jdiacomp.2007.09.001
Niki, I., Kelly, R. P., Ashcroft, S. J., and Ashcroft, F. M. (1989). ATP-sensitive K-channels in HIT T15 β-cells studied by patch-clamp methods, 86Rb efflux and glibenclamide binding. Pflugers Arch. 415, 47–55. doi: 10.1007/bf00373140
Ogden, C. L., Carroll, M. D., Kit, B. K., and Flegal, K. M. (2014). Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA 311, 806–814. doi: 10.1001/jama.2014.732
Patel, A. D., Gerzanich, V., Geng, Z., and Simard, J. M. (2010). Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J. Neuropathol. Exp. Neurol. 69, 1177–1190. doi: 10.1097/NEN.0b013e3181fbf6d6
Patel, T. B., Rashed, H. M., Dyson, J., and Waller, F. M. (1987). Stimulation of biliary glutathione secretion by sulfonylureas. Mol. Pharmacol. 31, 638–642.
Pistell, P. J., Morrison, C. D., Gupta, S., Knight, A. G., Keller, J. N., Ingram, D. K., et al. (2010). Cognitive impairment following high fat diet consumption is associated with brain inflammation. J. Neuroimmunol. 219, 25–32. doi: 10.1016/j.jneuroim.2009.11.010
Popoli, P., Pintor, A., Domenici, M. R., Frank, C., Tebano, M. T., Pezzola, A., et al. (2002). Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22, 1967–1975.
Portas, C. M., Thakkar, M., Rainnie, D. G., Greene, R. W., and McCarley, R. W. (1997). Role of adenosine in behavioral state modulation: a microdialysis study in the freely moving cat. Neuroscience 79, 225–235. doi: 10.1016/s0306-4522(96)00640-9
Prut, L., and Belzung, C. (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 463, 3–33. doi: 10.1016/s0014-2999(03)01272-x
Schwarzschild, M. A., Chen, J. F., and Ascherio, A. (2002). Caffeinated clues and the promise of adenosine A2A antagonists in PD. Neurology 58, 1154–1160. doi: 10.1212/wnl.58.8.1154
Shukitt-Hale, B. (1999). The effects of aging and oxidative stress on psychomotor and cognitive behavior. Age (Omaha) 22, 9–17. doi: 10.1007/s11357-999-0002-7
Simard, J. M., Kilbourne, M., Tsymbalyuk, O., Tosun, C., Caridi, J., Ivanova, S., et al. (2009a). Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. J. Neurotrauma 26, 2257–2267. doi: 10.1089/neu.2009.1021
Simard, J. M., Urovsky, V., Tsymbalyuk, N., Melnichenko, L., Ivanova, S., and Gerzanich, V. (2009b). Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 40, 604–609. doi: 10.1161/STROKEAHA.108.522409
Simard, J. M., Woo, S. K., Schwartzbauer, G. T., and Gerzanich, V. (2012). Sulfonylurea receptor 1 in central nervous system injury: a focused review. J. Cereb. Blood Flow Metab. 32, 1699–1717. doi: 10.1038/jcbfm.2012.91
Spielman, L. J., Little, J. P., and Klegeris, A. (2014). Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J. Neuroimmunol. 273, 8–21. doi: 10.1016/j.jneuroim.2014.06.004
Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., et al. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease-is this type 3 diabetes? J. Alzheimers Dis. 7, 63–80.
Stone, T. W. (2005). Adenosine, neurodegeneration and neuroprotection. Neurol. Res. 27, 161–168. doi: 10.1179/016164105x21896
Vainio, H., and Bianchini, F. (2002). “Weight control and physical activity,” in International Agency for Cancer Handbook of Cancer Prevention (Vol. 6), ed. A. Thomas (Lyon, France: IARC Press), 1–315.
Valladolid-Acebes, I., Fole, A., Martín, M., Morales, L., Victoria-Cano, M., Ruiz-Gayo, M., et al. (2013). Spatial memory impairment and changes in hippocampal morphology are triggered by high-fat diets in adolescent mice. Is there a role of leptin? Neurobiol. Learn. Mem. 106, 18–25. doi: 10.1016/j.nlm.2013.06.012
van der Heide, L. P., Ramakers, G. M., and Smidt, M. P. (2006). Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol. 79, 205–221. doi: 10.1016/j.pneurobio.2006.06.003
Vardy, E. R., Rice, P. J., Bowie, P. C., Holmes, J. D., Grant, P. J., and Hooper, N. M. (2007). Increased circulating insulin-like growth factor-1 in late-onset Alzheimer’s disease. J. Alzheimers Dis. 12, 285–290.
Wan, H., Aggleton, J. P., and Brown, M. W. (1999). Different contributions of the hippocampus and perirhinal cortex to recognition memory. J. Neurosci. 19, 1142–1148.
Wang, J., Freire, D., Knable, L., Zhao, W., Gong, B., Mazzola, P., et al. (2015). Childhood and adolescent obesity and long-term cognitive consequences during aging. J. Comp. Neurol. 523, 757–768. doi: 10.1002/cne.23708
Wannamethee, S. G., and Shaper, A. G. (1999). Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 22, 1266–1272. doi: 10.2337/diacare.22.8.1266
Wannamethee, S. G., Shaper, A. G., Durrington, P. N., and Perry, I. J. (1998). Hypertension, serum insulin, obesity and the metabolic syndrome. J. Hum. Hypertens. 12, 735–741. doi: 10.1038/sj.jhh.1000714
Watson, G. S., and Craft, S. (2004). Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer’s disease. Eur. J. Pharmacol. 490, 97–113. doi: 10.1016/j.ejphar.2004.02.048
Williams, C. L. (2001). “Can childhood obesity be prevented?,” in Primary and Secondary Preventive Nutrition, eds A. Bendich and R. J. Deckelbaum (Totowa, NJ: Springer), 185–204.
Xu, P. X., Wang, S. W., Yu, X. L., Su, Y. J., Wang, T., Zhou, W. W., et al. (2014). Rutin improves spatial memory in Alzheimer’s disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation. Behav. Brain Res. 264, 173–180. doi: 10.1016/j.bbr.2014.02.002
York, J. M., Blevins, N. A., Baynard, T., and Freund, G. G. (2012). Mouse testing methods in psychoneuroimmunology: an overview of how to measure sickness, depressive/anxietal, cognitive and physical activity behaviors. Methods Mol. Biol. 934, 243–276. doi: 10.1007/978-1-62703-071-7_13
Keywords: glyburide, anxiety, cognition, high-fat diet, oxidative stress
Citation: Gainey SJ, Kwakwa KA, Bray JK, Pillote MM, Tir VL, Towers AE and Freund GG (2016) Short-Term High-Fat Diet (HFD) Induced Anxiety-Like Behaviors and Cognitive Impairment Are Improved with Treatment by Glyburide. Front. Behav. Neurosci. 10:156. doi: 10.3389/fnbeh.2016.00156
Received: 21 April 2016; Accepted: 29 July 2016;
Published: 11 August 2016.
Edited by:
Amy Claire Reichelt, RMIT University, AustraliaReviewed by:
Guillaume Ferreira, Institut National de la Recherche Agronomique (INRA), FranceFiona Hollis, École Polytechnique Fédérale de Lausanne, Switzerland
Copyright © 2016 Gainey, Kwakwa, Bray, Pillote, Tir, Towers and Freund. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gregory G. Freund, freun@illinois.edu